Cidara Therapeutics Presents Preclinical Data On Novel Drug-Fc Conjugate CBO421 At SITC's 38 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics, Inc. (NASDAQ:CDTX) has presented new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data shows the potential of CBO421 to inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies. The company plans to advance this candidate into clinical trials for the treatment of solid tumors.
November 03, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cidara Therapeutics has presented promising preclinical data on its drug candidate, CBO421, indicating its potential to inhibit tumor growth. This could lead to the advancement of the drug into clinical trials.
The announcement of promising preclinical data on a drug candidate can be a positive signal for biotech companies like Cidara Therapeutics. If the drug advances into clinical trials and eventually gets approved, it could significantly boost the company's revenues and profitability, positively impacting the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100